Postdoctoral Fellow, Division of Hematology/Oncology, Department of Medicine, Nigel Mackman Laboratory, University of North Carolina at Chapel Hill, USA
Yohei Hisada earned his Ph.D. in the University of Tokyo in 2014. During his graduate studies, he developed a new method for cancer therapy/diagnosis by targeting fibrin in cancer tissue using a monoclonal antibody produced in Dr. Yasuhiro Matsumura’s laboratory. In 2014, he joined Dr. Nigel Mackman’s laboratory in the University of North Carolina at Chapel Hill. Currently, as a postdoctoral fellow, he is studying the mechanisms of cancer-associated venous thrombosis using mouse models.
Cancer patients have 4-7 fold increased risk of venous thromboembolism (VTE) compared with a general population ....
None of the information published on the ICTHC magazine website, in particular, information related to the choice and use of drugs, replaces the advice of a doctor.
Accept to continue
By registering to the newsletter, the User’s email address will be added to the contact list of ICTHIC Magazine, in order to receive email messages concerning the content published in ICTHIC Magazine and related promotional content/activities. Your email address may also be added to this list as a result of signing up to this Website. Personal Data collected: email address, first name, last name, profession.
ICTHIC CONFERENCE Newsletter By registering to the newsletter, the User’s email address will be added to the contact list of ICTHIC, in order to receive newsletters concerning the conference, such as Save the date, information about the meeting venue, the publication of the program, registration fees and deadline, abstract submission deadline and oral communication/poster instructions, hotel booking availability and deadline, social program for accompanying persons, the publication of speakers slides, photo/videogallery of the last edition and information about future editions of the conference. Your email address may also be added to this list as a result of signing up to this Website.